➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
Baxter
Boehringer Ingelheim
Merck

Last Updated: September 18, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,588,716

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,588,716
Title: Method for treating metabolic bone disease in mammals
Abstract:A method for treating or preventing metabolic bone disease characterized by loss of bone mass in mammals by administering 24-epi-1.alpha.,25-dihydroxy vitamin D.sub.2 alone or in combinations thereof with bone mobilization-inducing vitamin D derivatives to said mammals.
Inventor(s): DeLuca; Hector F. (Madison, WI), Schnoes; Heinrich K. (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:06/691,824
Patent Claims:1. A method for preventing or treating physiological disorders in mammals, which disorders are characterized by a requirement to regenerate or prevent loss of bone mass, which comprises administering to said mammals an amount of 1 alpha,25-dihydroxy-24-epi vitamin D.sub.2 sufficient to induce mineralization of bone and thereby to increase or prevent loss of net bone mass.

2. The method of claim 1 wherein the disorder is postmenopausal osteoporosis.

3. The method of claim 1 wherein the disorder is involutional osteoporosis.

4. The method of claim 1 wherein the disorder is senile osteoporosis.

5. The method of claim 1 wherein the disorder is steroid-induced osteoporosis.

6. The method of claim 2 wherein the compound is administered to women during and subsequent to menopause.

7. The method of claim 2 wherein the compound is administered to women prior to the onset of menopause.

8. The method of claim 1 wherein the compound is administered in an amount from about 0.5 microgram to about 25 micrograms per day.

9. The method of claim 1 wherein the compound, in solution in a liquid vehicle ingestible by and nontoxic to said mammals is administered orally in encapsulated form.

10. The method of claim 1 wherein 1.alpha.,25-dihydroxy-24-epi vitamin D.sub.2 is administered in combination with at least one hormone or vitamin D compound characterized by the ability to mobilize bone in vivo.

11. The method of claim 10 where the bone mobilization-inducing compound is selected from parathyroid hormone vitamin D.sub.3, vitamin D.sub.2 1.alpha.-hydroxyvitamin D.sub.3, 1.alpha.-hydroxyvitamin D.sub.2, 1.alpha.,25-dihydroxyvitamin D.sub.3, 1.alpha.,25-dihydroxyvitamin D.sub.2, 25-hydroxyvitamin D.sub.3, 25-hydroxyvitamin D.sub.2, 24-24-difluoro-25-hydroxyvitamin D.sub.3, 24,24-difluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 24-fluoro-25-hydroxyvitamin D.sub.3, 24-fluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 2.beta.-fluoro-25-hydroxyvitamin D.sub.3, 2.beta.-fluoro-1.alpha.-hydroxyvitamin D.sub.3, 2.beta.-fluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 26,26,26,27,27,27-hexafluoro-25- hydroxyvitamin D.sub.3, 26,26,26,27,27,27-hexafluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 24,25-dihydroxyvitamin D.sub.3, 1.alpha.,24,25-trihydroxyvitamin D.sub.3, 25,26-dihydroxyvitamin D.sub.3, 1.alpha.,25,26-trihyroxyvitamin D.sub.3.

12. The method of claim 10 wherein the administration is the pulse regimen comprising initially administering a hormone or vitamin D compound characterized by its ability to mobilize bone in vivo for a time sufficient to induce new bone resorption cavities, then discontinuing such administration and commencing the administration of 24-epi-1.alpha.,25-dihydroxyvitamin D.sub.2 until net bone formation has been realized.

13. The method of claim 11 wherein the administration is the pulse regimen.

14. The method of claim 13 wherein the vitamin D compound is 1.alpha.,25-dihydroxyvitamin D.sub.3 or 1.alpha.,25-dihydroxyvitamin D.sub.2.

15. The method of claim 13 wherein the hormone is parathyroid hormone.

16. A pharmaceutical composition comprising 1.alpha.,25-dihydroxy-24-epi vitamin D.sub.2 and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising 1 alpha,25-dihydroxy-24-epi-vitamin D.sub.2 and at least one bone mobilization inducing compound selected from the group consisting of the bone-mobilization inducing compounds set forth in claim 12.

18. The pharmaceutical composition of claim 17 wherein the bone mobilization-inducing compound is a vitamin D derivative selected from the group consisting of 25-hydroxyvitamin D.sub.3, 25-hydroxyvitamin D.sub.2, 1.alpha.-hydroxyvitamin D.sub.3, 1.alpha.-hydroxyvitamin D.sub.2, 1.alpha.,25-dihydroxyvitamin D.sub.3, 1.alpha.,25-dihydroxyvitamin D.sub.2, 24,24-difluoro-25-hydroxyvitamin D.sub.3, 24,24-difluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 24-fluoro-25-hydroxyvitamin D.sub.3, 24-fluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 26,26,26,27,27,27-hexafluoro-1.alpha.,25-dihydroxyvitamin D.sub.3, 26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D.sub.3, 2.beta.-fluoro-1.alpha.-hydroxyvitamin D.sub.3, 2.beta.-fluoro-25-hydroxyvitamin D.sub.3, 24,25-dihydroxyvitamin d.sub.3, 1.alpha.,24,25-trihydroxyvitamin D.sub.3, 25,26-dihydroxyvitamin D.sub.3, 1.alpha.,25,26-trihydroxyvitamin D.sub.3.

Details for Patent 4,588,716

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2004-05-04 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2004-05-04 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2004-05-04 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ⤷  Free Forever Trial Wisconsin Alumni Research Foundation (Madison, WI) 2004-05-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
Colorcon
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.